Fund managers were being offered $US150 million ($226 million) worth of shares in cancer treatment hopeful Telix Pharmaceuticals after Tuesday’s close, as JPMorgan got going on the delta placement leg of a $600 million convertible notes deal in lieu of an abandoned Nasdaq listing.
Terms sent to potential investors show Telix shares were being offered under a variable price book build at $18.60 a share to $19.60. That represented a 3.5 per cent to 8.4 per cent discount to the last close. The book was due to shut at 7:30pm.
Source - Australian Financial Review
Ann: Telix Announces A$600 Million Convertible Bonds Offering, page-34
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.07 |
Change
-1.245(6.13%) |
Mkt cap ! $6.399B | |||
| Open | High | Low | Value | Volume |
| $18.92 | $19.57 | $18.68 | $82.01M | 4.304M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 4 | $19.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.07 | 2504 | 20 |
View Market Depth
| Last trade - 15.10pm 24/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |